Changes in Bile Acid Profile After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Metabolic Profile and Fatty Liver Disease

Obesity Surgery

Volumn 26, Issue 6, 2016, Pages 1195-1202

  Belgaumkar, Ajay P ^a   Vincent, Royce P ^a   Carswell, Kirstin A ^a   Hughes, Robin D ^a   Alaghband Zadeh, Jamie ^a   Mitry, Ragai R ^a   le Roux, Carel W ^b   Patel, Ameet G ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Bariatric surgery; Bile acids; Sleeve gastrectomy

Indexed keywords

BILE ACID; CHOLIC ACID; CYTOKERATIN 18; FIBROBLAST GROWTH FACTOR 19; GLYCINE; TAURINE; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; HUMAN; INSULIN RESISTANCE; LAPAROSCOPIC SURGERY; LIQUID CHROMATOGRAPHY; LIVER INJURY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SLEEVE GASTRECTOMY; TANDEM MASS SPECTROMETRY; ADOLESCENT; BLOOD; COMPLICATION; GASTRECTOMY; LAPAROSCOPY; METABOLIC SYNDROME X; MIDDLE AGED; MORBID OBESITY; PROCEDURES; PROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; AGED; BILE ACIDS AND SALTS; BIOMARKERS; FATTY LIVER; FEMALE; GASTRECTOMY; HUMANS; LAPAROSCOPY; MALE; METABOLIC SYNDROME; MIDDLE AGED; OBESITY, MORBID; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84940702226     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-015-1878-1     Document Type: Article

References (52)

1. Das UN. Obesity, metabolic syndrome X, and inflammation. Nutrition. 2002;18(5):430–2.
2. Caiazzo R et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg. 2014;260(5):893–8. discussion 898–9.
3. Tran A, Gual P. Non-alcoholic steatohepatitis in morbidly obese patients. Clin Res Hepatol Gastroenterol. 2013;37(1):17–29.
4. Wieckowska A et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44(1):27–33.
5. Feldstein AE et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50(4):1072–8.
6. Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes. 2013;2013:839275.
7. Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal. 2010;8:e005.
8. Chen X et al. TGR5: a novel target for weight maintenance and glucose metabolism. Exp Diabetes Res. 2011;2011:853501.
9. Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol. 2013;86(11):1517–24.
10. Haeusler RA et al. Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes. 2013;62(12):4184–91.
11. Gerhard GS et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013;36(7):1859–64.
12. Jansen PL et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis. 2011;29(1):48–51.
13. Patti ME et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring). 2009;17(9):1671–7.
14. Pournaras DJ et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153(8):3613–9.
15. Steinert RE, et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity (Silver Spring). 2013.
16. Haluzikova D et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity (Silver Spring). 2013;21(7):1335–42.
17. Bechmann LP et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology. 2013;57(4):1394–406.
18. Myronovych A et al. Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner. Obesity (Silver Spring). 2014;22(2):390–400.
19. Ryan KK et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509(7499):183–8.
20. Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2012;12:CD009361.
21. Beysen C et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia. 2012;55(2):432–42.
22. Chamulitrat W et al. Ursodeoxycholyl lysophosphatidylethanolamide inhibits lipoapoptosis by shifting fatty acid pools toward monosaturated and polyunsaturated fatty acids in mouse hepatocytes. Mol Pharmacol. 2013;84(5):696–709.
23. Xiang Z et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013;13:140.
24. Owen-Smith A et al. A NICE example? Variation in provision of bariatric surgery in England. BMJ. 2013;346:f2453.
25. MacLaughlin HL et al. Laparoscopic sleeve gastrectomy is a novel and effective treatment for obesity in patients with chronic kidney disease. Obes Surg. 2012;22(1):119–23.
26. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–95.
27. Tagliacozzi D et al. Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin Chem Lab Med. 2003;41(12):1633–41.
28. Brunt EM et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810–20.
29. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am. 2008;37(3):635–46. viii-ix.
30. Carswell KA, et al. A systematic review and meta-analysis of the effect of gastric bypass surgery on plasma lipid levels. Obes Surg, 2015.
31. Rao SR. Inflammatory markers and bariatric surgery: a meta-analysis. Inflamm Res. 2012;61(8):789–807.
32. Terra X et al. Long-term changes in leptin, chemerin and ghrelin levels following different bariatric surgery procedures: Roux-en-Y gastric bypass and sleeve gastrectomy. Obes Surg. 2013;23(11):1790–8.
33. Dali-Youcef N et al. Metabolic inflammation: connecting obesity and insulin resistance. Ann Med. 2013;45(3):242–53.
34. Xu XJ et al. What distinguishes adipose tissue of severely obese humans who are insulin sensitive and resistant? Curr Opin Lipidol. 2013;24(1):49–56.
35. Diab DL et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol. 2008;6(11):1249–54.
36. Kahraman A et al. Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients. Clin Sci (Lond). 2013;125(8):391–400.
37. Melissas J et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. Ann Surg. 2013;258(6):976–82.
38. Pournaras DJ, le Roux CW. Are bile acids the new gut hormones? Lessons from weight loss surgery models. Endocrinology. 2013;154(7):2255–6.
39. Kohli R et al. A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology. 2013;154(7):2341–51.
40. Kong LC et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr. 2013;98(1):16–24.
41. Esteve E, Ricart W, Fernandez-Real JM. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance? Curr Opin Clin Nutr Metab Care. 2011;14(5):483–90.
42. Monte SV et al. Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. Surgery. 2012;151(4):587–93.
43. Damms-Machado A et al. Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption. Biomed Res Int. 2015;2015:806248.
44. Pathil A et al. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology. 2012;55(5):1369–78.
45. Buko VU et al. Ursodeoxycholic acid dose-dependently improves liver injury in rats fed a methionine- and choline-deficient diet. Hepatol Res. 2011;41(7):647–59.
46. Luo L et al. Evaluation of serum bile acid profiles as biomarkers of liver injury in rodents. Toxicol Sci. 2014;137(1):12–25.
47. Aranha MM et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2008;20(6):519–25.
48. Myronovych A et al. The role of small heterodimer partner in nonalcoholic fatty liver disease improvement after sleeve gastrectomy in mice. Obesity (Silver Spring). 2014;22(11):2301–11.
49. Illan-Gomez F et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg. 2012;22(6):950–5.
50. Mudaliar S et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145(3):574–82 e1.
51. Li JV et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut. 2011;60(9):1214–23.
52. Werling M et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol. 2013;48(11):1257–64.